Table 3 Response to Prior Lines in Regorafenib and Rechallenge Groups
Regorafenib (n = 266) | Rechallenge (n = 128) | p | |
|---|---|---|---|
Response to both prior lines of treatment (CR + PR + SD), n(%) | 172 (64.6) | 84 (65.6) | .851 |
Response to one prior line of treatment (CR + PR + SD), n(%) | 79 (29.6) | 44 (34.3) | .348 |
Progression under both lines of treatment, n(%) | 15(5.1) | 0(0) | .004 |